INDIA'S INVESTING & TRADING TOOLS RESEARCH LIBRARYPublisher relationship disclosed in our editorial policy
Reviews / Screener.in

Screener.in Review (2026): Features, Pricing, Pros & Cons

Best for: Custom fundamental queries. Reference pricing: ₹4,999/year Active Investor. Free access: Yes.

What is Screener.in and who is it best for?

A robust financial-query and company-analysis platform for investors who want precise control over fundamental screening logic. Value, quality and long-term investors who analyse company statements deeply. As with every investing research tool, your choice should depend on the questions you ask, how often you need refreshed information and whether you can verify results against primary disclosures. We describe documented capabilities rather than claiming to have run an independent latency or investment-performance test.

What are the main features of Screener.in?

  • Formula-based custom stock screens
  • Multi-year company financial statements
  • Peer comparisons and segment data
  • Excel automation and watchlists
  • Stock alerts and financial charts

The most useful feature is the one that fits the actual process you follow. Evaluate the available filters, the datasets they operate on, how they handle saved research and whether the interface helps you confirm a screening result. Features advertised on a product page can change across plans or during promotional periods. Check the linked vendor documentation for current entitlements before purchasing.

How much does Screener.in cost in 2026?

Reference pricing: ₹4,999/year Active Investor. Free access: Yes. Prices or promotions can change. For the current offering and any taxes or add-on exchange data costs, review the official source. Do not choose a platform solely because its subscription price is lower. Compare the features you actually use and whether a free account already solves the research problem.

What are Screener.in's advantages and disadvantages?

Advantages

  • Powerful custom formulas
  • Detailed financial history
  • Useful free research capabilities

Limitations

  • Requires comfort with financial ratios
  • Not a live technical scanning platform

Who should not choose Screener.in?

If you need predominantly technical signals, consider Chartink or TradingView. If your research is infrequent, begin with a free plan before assuming that a paid package will improve your decisions. A screener shows rule matches rather than validated investment opportunities, and any company on a shortlist still requires independent review of financial statements, disclosures, valuation and risks.

Is Screener.in worth using in 2026?

Screener.in is worth considering if your workflow specifically needs custom fundamental queries. Its approach is financial statements, ratios, custom query expressions. The key limitation to understand is: Less suitable for intraday technical scanning. Explore the full stock screener ranking or compare competing tools before deciding whether to subscribe.

FAQs about Screener.in

Does Screener.in offer free access?

Yes is the published availability of free access in our comparison. Confirm current sign-up access and limits on the vendor website. Some products limit exports, data intervals, alerts or advanced analysis by tier.

Is Screener.in a stock recommendation service?

This profile evaluates screening and research capabilities, not the suitability of any security for a specific investor. Research scores, scans and generated explanations do not guarantee performance. Consider the product documentation and use appropriate financial advice when required.

What is a good alternative to Screener.in?

A good alternative depends on your use case: Bullrun for guided Indian stock research, Screener.in for fundamental query flexibility, Chartink for custom technical scans, and TradingView for advanced charts. Different tools can be complementary rather than direct replacements.

Primary source: Screener.in product information. All prices and features are subject to change.

Educational tool analysis only. No investment advice. Our publisher is associated with Bullrun; see our disclosure.